









Markets
/
Stocks
/
nasdaq-vcyt
/

Veracyte Inc

VCYT

30.010USD

-2.790-8.51%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

620.90MMarket Cap

35.54P/E TTM



Veracyte Inc

30.010

-2.790-8.51%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Veracyte Inc

Currency: USD Updated: 2026-03-27

Key Insights

Veracyte Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.90.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Veracyte Inc's Score

Industry at a Glance

Industry Ranking

20 / 391

Overall Ranking

100 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Veracyte Inc Highlights

StrengthsRisks

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 43.23% year-on-year.

Fairly Valued

The company’s latest PE is 35.54, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 89.69M shares, decreasing 3.98% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 53.00 shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

48.900

Target Price

+49.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Veracyte Inc is 9.28, ranking 5 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 140.64M, representing a year-over-year increase of 18.55%, while its net profit experienced a year-over-year increase of 704.79%.

Score

Industry at a Glance

Previous score

9.28

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.71

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Veracyte Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Veracyte Inc is 5.61, ranking 372 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 35.54, which is 311.35% below the recent high of 146.20 and 1004.38% above the recent low of -321.44.

Score

Industry at a Glance

Previous score

5.61

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Veracyte Inc is 8.15, ranking 157 out of 391 in the Biotechnology & Medical Research industry. The average price target is 48.00, with a high of 57.00 and a low of 43.00.

Score

Industry at a Glance

Previous score

8.15

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

48.900

Target Price

+49.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Veracyte Inc

VCYT

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Veracyte Inc is 6.64, ranking 176 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 34.74 and the support level at 27.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.04

Change

-0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.016

Neutral

RSI(14)

33.275

Neutral

STOCH(KDJ)(9,3,3)

32.280

Sell

ATR(14)

1.412

Low Volatility

CCI(14)

-196.704

Sell

Williams %R

88.254

Oversold

TRIX(12,20)

-0.487

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

32.416

Sell

MA10

32.638

Sell

MA20

33.197

Sell

MA50

36.080

Sell

MA100

39.592

Sell

MA200

34.801

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Veracyte Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 113.46%, representing a quarter-over-quarter increase of 2.66%. The largest institutional shareholder is The Vanguard, holding a total of 8.49M shares, representing 10.68% of shares outstanding, with 1.43% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.32M

+84.79%

The Vanguard Group, Inc.

Star Investors

8.49M

+5.00%

Artisan Partners Limited Partnership

7.37M

+16.59%

Fidelity Management & Research Company LLC

5.75M

-17.05%

State Street Investment Management (US)

4.20M

+32.49%

ARK Investment Management LLC

Star Investors

4.47M

+17.52%

Dimensional Fund Advisors, L.P.

3.12M

+3.17%

Wellington Management Company, LLP

3.37M

-2.89%

Geode Capital Management, L.L.C.

1.89M

-2.07%

ArrowMark Colorado Holdings, LLC

2.55M

-1.28%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Veracyte Inc is 5.68, ranking 41 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.